Analyst Profile

Followed by 186 followers
.
Gregory Renza

Gregory Renza

RBC Capital
Wall Street Analyst
#7,127 out of 8,141 Wall Street Analysts
#21,418 out of 24,284 experts

Success Rate

33%
73 out of 219 transactions made a profit

Average Return

-3.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Gregory Renza's trades since 2015 and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -3.4% per rating.

Stock Rating Distribution

312Ratings
76.92% Buy
23.08% Hold
0.00% Sell
Distribution of Gregory Renza's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Aptose Biosciences
(APTO)
Rating:Buy
Date:Mar 01, 2019 - Mar 01, 2020
Return:+347.40%
The most profitable rating made by Gregory Renza

Gregory Renza's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Biogen
Sep 08, 2015
Buy
Assigned
$348.00
(14.04% Upside)
1Ratings
0%
-0.30%
CELG
Celgene
Sep 08, 2015
Buy
Initiated
1Ratings
0%
-12.40%
Gilead Sciences
Sep 10, 2015
Hold
Assigned
$115.00
(33.32% Upside)
1Ratings
0.00%
ARQL
Arqule
Dec 10, 2019
Hold
Downgraded
6Ratings
100%
+169.28%
PTLA
Portola Pharma
Apr 23, 2020
Buy
Initiated
1Ratings
100%
+160.10%
Iterum Therapeutics
Nov 12, 2021
Hold
Reiterated
$15.00
(1027.82% Upside)
14Ratings
0%
-57.21%
Gamida Cell
Nov 15, 2021
Buy
Reiterated
$10.00
(525.00% Upside)
12Ratings
30%
-29.24%
Aprea Therapeutics
Mar 16, 2022
Hold
Reiterated
$4.00
(938.96% Upside)
18Ratings
0%
-72.91%
GBT
Global Blood Therapeutics
Aug 08, 2022
Hold
Downgraded
$68.50
(0.01% Upside)
15Ratings
64%
+48.65%
Nurix Therapeutics
Oct 06, 2022
Buy
Reiterated
$39.00
(228.84% Upside)
5Ratings
50%
+3.75%
List of latest recommendations made by Gregory Renza. Click to expand and see Gregory Renza's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >